Called Novasenta, the company is focused on the tumor microenvironment and will leverage its machine-learning platform to pinpoint targets for drug development. It aims to launch its first clinical trial by the end of 2023.
At least one biotech has lined up for a shot at the public markets in 2017. Cancer immunotherapy company Jounce Therapeutics filed with the SEC on Friday, outlining plans for an IPO that could be worth up to $75 million.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.